hVIVO (LON:HVO) Trading Up 11.9% – Still a Buy?

hVIVO plc (LON:HVO)’s stock price rose 11.9% during trading on Friday . The company traded as high as GBX 7.50 and last traded at GBX 7.50. Approximately 4,541,654 shares changed hands during trading, an increase of 59% from the average daily volume of 2,858,300 shares. The stock had previously closed at GBX 6.70.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Stifel Nicolaus reiterated a “hold” rating and issued a GBX 10 price objective on shares of hVIVO in a research note on Thursday, May 7th. Shore Capital Group reaffirmed a “buy” rating on shares of hVIVO in a report on Wednesday, April 22nd. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, hVIVO presently has an average rating of “Moderate Buy” and a consensus target price of GBX 15.

hVIVO Price Performance

The business’s fifty day moving average price is GBX 7.57 and its 200 day moving average price is GBX 7.43. The company has a debt-to-equity ratio of 38.75, a current ratio of 1.63 and a quick ratio of 1.16. The stock has a market cap of £51.63 million, a P/E ratio of -8.62 and a beta of 1.71.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.